Cardiol Therapeutics Inc. — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · Canada
Last price 1.17 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 139.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38, a novel subcutaneously administered drug formulation of cannabidiol for the treatment of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Details
| Name | Cardiol Therapeutics Inc. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 18 |
| Founded | 2017 |
| Ceo | David Elsley |
| Country | Canada |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| Isin | CA14161Y2006 |
| Cusip | 14161Y200 |
| Cik | 1702123 |
| Sic | 2836 |
| Share Class | Class A Shares |
Key executives
| Name | Title |
|---|---|
| David G. Elsley MBA | President, Chief Executive Officer and Director |
| Christopher J. Waddick C.A., C.M.A., CPA, MBA | Chief Financial Officer, Corporate Secretary and Director |
| Bernard Lim B.Sc. | Chief Operating Officer |
| Dr. Andrew Warwick Hamer M.D. | Chief Medical Officer and Head of Research and Development |
| Trevor Burns | Investor Relations |
| John A. Geddes BSCPT, MBA | Vice President of Corporate Development |
Contact
| Address | 2265 Upper Middle Road East, Suite 602, Oakville, ON L6H 0G5, Canada |
| Phone | 289 910 0850 |
| Website | https://www.cardiolrx.com |